Compare FLYW & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLYW | INSP |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2021 | 2018 |
| Metric | FLYW | INSP |
|---|---|---|
| Price | $16.03 | $41.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 16 |
| Target Price | $16.21 | ★ $94.00 |
| AVG Volume (30 Days) | ★ 2.2M | 1.1M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 450.00 | 179.43 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $623,025,000.00 | $82,050,000.00 |
| Revenue This Year | $19.68 | $8.02 |
| Revenue Next Year | $15.25 | $8.11 |
| P/E Ratio | $160.60 | ★ N/A |
| Revenue Growth | 26.59 | ★ 62.18 |
| 52 Week Low | $9.97 | $39.61 |
| 52 Week High | $18.05 | $151.41 |
| Indicator | FLYW | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 60.70 | 32.91 |
| Support Level | $12.91 | N/A |
| Resistance Level | $18.05 | $59.40 |
| Average True Range (ATR) | 0.80 | 2.84 |
| MACD | 0.01 | -0.86 |
| Stochastic Oscillator | 58.32 | 12.43 |
Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements, namely a payments platform, a proprietary payment network, and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.